Click here to load reader
Upload
michelle-avery
View
116
Download
0
Embed Size (px)
DESCRIPTION
102 年度 癌症診療品質認證 醫院 檢討會. 主辦機構:國民健康署 承辦機構: 國家衛生研究院 癌症研究所 TCOG 簡報日期: 102 年 11 月 01 日. 大綱. 認證作業程序檢討 認證基準檢討 綜合討論. 認證作業程序檢討. 申請程序. 102 年 3 月 1 日至 102 年 3 月 31 日 下午五點前,填妥「癌症診療品質認證申請表」一份及 「癌症診療品質認證-醫院自評書」一式三份 (其中二份請勿裝訂) 及電子檔一份 ,寄達健康署所委託之機構,以完成報名之申請。 - PowerPoint PPT Presentation
Citation preview
102 TCOG102 11 01
*
*
10231102331
https://pfp.bhp.doh.gov.tw48*
*
*
3055305(12:30-13:20)3004020
102*
1025101918=94.74%738.89% 844.44% 316.67%*
-1
2
*
*
N%211.11 1688.89
*
N%00.0018100.00N=171617131191
*
N%1266.67633.33 SOP
*
N%211.111688.89844.44738.89TCOG316.67 1372.22 00.00 527.78 32
-2
?*
*
N%00.0018100.003N=1771715
*
N%3015.56 1794.44 3001688.89 211.11
*
N%2015.561794.44
1794.4415.56
*
N%738.891055.5615.56211.111688.89
*
*
4 (1 )1 6 1 17 6 6 1 2 1 1 36 10 2
*
Rating A 10Rating A + Rating B 26 Rating D + Rating E0 10 Rating B 5 Rating A Rating A + Rating B > 10 Rating D 3 Rating E0 Rating A + Rating B 10 Rating D 4 Rating E 1
()
B
1.22.43.23.3.33.53.6.23.6.33.104.15.1*
*
*
*
1.1Rating ERating DRating C50
*
1.1Rating BC Rating AB1.275 %
*
1.1
*
1.1
1.1*()
*
1.2 1234
*
1.2 Rating ERating DRating C Rating CRating BC
*
1.2 Rating AB 1 ~ 4
*
1.2
1.2*)
*
1.3 Rating ERating DRating CRating CRating BCPDCARating ABPDCA
*
1.312
1.3*
*
1.4 1AJCC 23 4
*
1.4 1. 1AJCC 23
*
1.4
1.4*
*
*
2.1Rating ERating DRating DRating CRating BC
*
2.1Rating AB3000130002
*
*
2.1 102 99
2.1 *
*
2.2Rating ERating DRating D95%98%90%95%Rating C98%95%98%Rating B98%98%95%Rating A98
*
2.2( 97 -9999100(1)( A / B ) 100%100A98B98 + 98
*
2.2(2)E+F/ D 100% (100)D98E9898F9898
*
2.2(3)G / H 100%100G98H98
2.
*
2.3Rating ERating DRating CRating CRating B C Rating A B
*
2.3
*
2.3Rating A 3 123
2.3 *
*
2.4 Rating ERating DRating CRating CRating BCRating AB
*
2.4 1234Class1~25
2.4*
*
2.5Class1~2Rating E Rating DRating C Rating C80
*
2.5Rating BC80 ~ 95%Rating AB 95%
*
2.5Class 1~ 2Stage
*
2.5123 Class 1~245
*
2.5K / L 100 K L 10%Class 1~2
*
962.13Tumor Size96983.4T Clinical T1151172.14Regional Lymph Nodes Examined991003.5N Clinical N1181192.15Regional Lymph Nodes Positive1011023.6M Clinical M1201213.7Clinical Stage Group122124
*
3.10T Pathologic T127129Other Staging System FIGO3.11N Pathologic N130131Other Staging SystemBCLC1013.12M Pathologic M1321333.13Pathologic Stage Group134136Other Staging Systemhistology101
2.52.4*
*
2.6 Class 0 ~ 3Rating ERating DRating CRating BCRating AB
*
2.61Class 0~32Class 1~2 2 5Class 0334:56
2.6
*
*
*
3.1Rating ERating DRating CRating CRating BC
*
3.1Rating AB /
*
3.11 peer review article234
*
3.1Rating A Hodgkin lymphomaBDiffuse large B cell lymphoma Follicular lymphoma
3.1*
*
3.2 Rating ERating DRating CRating C70 %Rating BC50%
*
3.2 Rating ABClass 1~2
*
3.2 Class 1~21 22
3
1,000 61,001~2,00092,001 12
*
3.2 123minimum requirement12345comorbidity6regimensdose
*
3.2 C Bsummary note
3.2 regimenRTdose *
*
3.3 3.3.1 Rating E20 %Rating D20 %40 %Rating C40 %60 %Rating B60 %80 %Rating A80 %
*
3.3.112T NM AJCC
*
3.3.1
1272411 [ ( 27 + 14 + 01 ) / ( 212 ) ] 100 %18 / 24 100 %75 %Rating B3.2
3.3.1
*
*
3.3.2 Rating E20 %Rating D20 %40 %Rating C40 %60 %Rating B60 %80 %Rating A80 %
*
3.3.2123
*
3.3.2
12833211 [ ( 38 + 23 + 11 ) / ( 312 ) ] 100 %31 / 36 100 %86 %Rating A3.2
3.3.2 *
*
3.3.3 Rating E20 %Rating D20 %40 %Rating C40 %60 %Rating B60 %80 %Rating A80 %
*
3.3.3 123Neoadjuvant
*
3.3.3
94322 211 [ ( 34 + 22 + 12 + 01 ) / ( 39 ) ] 100 %18 / 27 100 %67 % Rating B 3.2
3.3.3*1.
*
3.3.4Rating E20 %Rating D20 %40 %Rating C40 %60 %Rating B60 %80 %Rating A80 % curative intent
*
3.3.4curative intent123 1 13 C
*
3.3.41.
92 332311 [ ( 32 + 23 + 13 + 01 ) / ( 39 ) ] 100 %15 / 27 100 %56 % Rating C2. 3.2
3.3.4 *
*
3.4Rating ERating DRating CRating CRating BC70 %
*
3.4Rating AB
*
3.4
*
3.424B1502
*
1. 2. 3. 4. 5. 6. ()
*
7. 8. 9. 10. 11. 12.
3.4
*
*
3.5 Rating ERating DRating CRating C10%
*
3.5 Rating BC10%5%Rating AB10%20%10%
*
3.5 Class 1~3
*
3.5 12303123
*
3.5 1234
*
3.5 1 conclusion or recommendation 2 process
3.5 10%50%*
*
3.63.6.1Rating ERating DRating CRating C
*
3.6.1Rating BCRating AB
*
3.6.1AdjuvantNeoadjuvantConcurrent Chemoradiotherapy CCRT
*
3.6.1*
*
3.6.2 Rating ERating DRating CRating C 3.6.1 prescriptionRating BCprescriptionRating AB
*
3.6.2 1.prescription
3.6.2
*
*
3.6.3 Rating ERating DRating CRating CRating BCRating AB
*
3.6.3
*
3.6.3 123
*
3.6.3
*
3.6.3 (spill kits)1
Class II BClass III
*
3.6.3 2
3.6.3
*
*
3.6.4 Rating ERating DRating CRating CRating BCRating AB
*
3.6.412
*
3.6.4
*
3.6.43.6.3 1
3.6.4 *
*
3.73.7.1Rating ERating DRating CRating C
*
3.7.1Rating BCRating AB
*
3.7.112 permanent section Her-2 /neuCAPTAFISO15189
3.7.1
*
*
3.7.2Rating ERating DRating CRating CRating BC
*
3.7.2Rating AB
3.7.2
*
*
3.8 Rating E Rating DRating CRating CRating BC
*
3.8Rating AB
*
3.8 CT MRI
3.8
*
*
3.9Rating ERating DRating CRating C (curative intent) Rating BCRating C (curative intent)
*
3.9Rating ABRating C curative intent
*
3.9 12CTVPTV
*
3.91peer review article234
*
3.912CC E
3.9(:) *
*
3.10 Rating ERating DRating CRating CRating BRating A
*
3.10 102
3.10 *
*
*
4.1 123 / 4Rating E
Rating DRating C
*
4.1 Rating CRating BCRating AB
*
4.1 /Port-AHickmanPICC /
*
4.1 3.6.4
4.1
*
*
4.2 Rating E Rating DRating CRating C Rating BC Rating AB
*
4.23.6.4
4.2
*
*
4.3 Rating ERating DRating CRating CRating BRating A
*
4.3
*
4.3 1.3 3 41 3.6.4
4.3*
*
4.4Rating E Rating DRating CRating C
*
4.4Rating BC20 8020Rating AB 6 50%
*
4.420
*
4.4 6 6 6
4.4850%
*
*
4.5Rating ERating DRating CRating C50Rating BCClass1~2400
*
4.5Rating AB10299
*
4.511 2 234 C
4.5*
*
4.6 Rating ERating DRating CRating CRating BC
*
4.6Rating AB
*
4.6()
*
4.6 A intake BMI
4.6*
*
*
5.1 Rating ERating DRating C Rating CRating B CRating A B
*
5.1 2 PDCA
5.1 2
*
*
5.2 Rating ERating DRating CRating BCRating AB
*
5.2
*
*
6.1 Class1~22,000AIRBClass1~22,0001A
*
6.1 IRB
6.1(:) *
*
*